ESCMID 2026 Shifts Cancer Microbiome Focus to Function, With 46,000-Patient Data Linking Antibiotics to Worse Response
Updated
Updated · emjreviews.com · Jun 1
ESCMID 2026 Shifts Cancer Microbiome Focus to Function, With 46,000-Patient Data Linking Antibiotics to Worse Response
2 articles · Updated · emjreviews.com · Jun 1
Summary
ESCMID Global 2026 spotlighted microbial function—not just bacterial composition—as a key driver of how patients respond to cancer therapy, especially immunotherapy.
Data presented at the meeting tied gut microbiome activity to stronger antitumour immunity, while faecal microbiota transplants from immunotherapy responders produced clinical benefit in a subset of refractory melanoma cases.
More than 46,000 patients across over 100 studies showed poorer outcomes when antibiotics were used near immunotherapy, with broad-spectrum and combination regimens causing the greatest harm through microbiome disruption.
Early studies of prebiotics such as camu camu found improved outcomes despite little change in microbiome composition, reinforcing the view that metabolomic pathways like bile acid and tryptophan metabolism matter more than taxonomy.
Trials including FMT-LUMINate and the Phase II TACITO study reported encouraging signals across melanoma, non-small cell lung cancer and renal cell carcinoma, though routine use still faces standardisation, scalability and regulatory hurdles.
Since antibiotics can sabotage cancer treatment, are new microbiome-sparing drugs the key to improving patient survival?
Beyond fecal transplants, could precisely engineered 'probiotic pills' become a standard part of future cancer therapy?
Will decoding our gut microbiome become as crucial as genetics in personalizing cancer treatment?
From Species to Function: The Paradigm Shift in Cancer Microbiome Research and Its Clinical Impact
Overview
The ESCMID Global 2026 Congress in Copenhagen marked a turning point in cancer microbiome research, shifting the focus from simply identifying which bacteria are present to understanding what these microbes actually do in the body. Thanks to new sequencing technologies and bioinformatics tools, scientists can now explore microbial metabolic pathways and gene expression in detail. This functional approach is helping predict how patients will respond to cancer therapies and improve outcomes. By moving beyond cataloging species to uncovering their roles and activities, researchers are opening new possibilities for personalized cancer treatment and better patient care.